Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of Protein and Amino Acid Supplementation on Physical Performance in Patients With Chronic Heart Failure　- A Systematic Review and Meta-Analysis.

Circulation reports·2026

Same author

Long-term Safety and Efficacy of Bempedoic Acid in Japanese Patients with Hypercholesterolemia: the CLEAR-J LONG.

Journal of atherosclerosis and thrombosis·2025

Same author

Three-Year Outcome of Drug Coated Balloon Angioplasty Following Atherectomy for Severely Calcified Coronary Lesions.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025

Same author

Successful Treatment of Infective Endocarditis at 33 Weeks' Gestation Causing Acute Left Heart Failure.

Clinical case reports·2025

Same author

A male patient with pseudoxanthoma elasticum caused by isodisomy of chromosome 16 containing a nonsense variant of the <i>ABCC6</i> gene: A quarter-century treatment experience.

Atherosclerosis plus·2025

Same author

Circulating type IV collagen 7S concentrations are associated with left atrial remodeling indices in patients with atrial fibrillation.

The Journal of international medical research·2025

Same journal

Optimization of Infectious Disease Treatment via Clinical Practice-Based Personalized Therapy and Big Data Analysis.

Biological & pharmaceutical bulletin·2026

Same journal

Development of Nucleic Acid-Loaded Nanobubbles for Ultrasound-Mediated Therapeutic Applications.

Biological & pharmaceutical bulletin·2026

Same journal

An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia.

Biological & pharmaceutical bulletin·2026

Same journal

A Quantitative in Vitro Framework Reveals State-Dependent Pharmacological Responses to Repeated Inflammatory Stimulation in Synovial Fibroblasts.

Biological & pharmaceutical bulletin·2026

Same journal

Pinolenic Acid Inhibits Prostanoid TP Receptor-Mediated Contraction in Porcine Coronary Arteries.

Biological & pharmaceutical bulletin·2026

Same journal

Lipopolysaccharide-Induced Changes in Facial Expression and Orofacial Movement in Mice.

Biological & pharmaceutical bulletin·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Trastuzumab Cardiotoxicity: Mechanism and Management.

Minoru Wakasa¹, Miharu Masaki¹, Kouji Kajinami¹

¹Department of Cardiology, Kanazawa Medical University.

Biological & Pharmaceutical Bulletin

|August 31, 2025

Summary

This summary is machine-generated.

Trastuzumab is a vital breast cancer drug, but it can cause heart problems. Understanding its cardiac risks, diagnosis, and treatments is crucial for patient safety.

Keywords:

cardiotoxicity human epidermal growth factor receptor type 2 trastuzumab

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Experiment Videos

Last Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Area of Science:

Oncology
Cardiology
Pharmacology

Background:

Trastuzumab is a widely used breast cancer therapy.
It carries a risk of cardiotoxicity, including arrhythmia, cardiomyopathy, and heart failure.
Mechanisms of trastuzumab-induced cardiotoxicity are being elucidated, potentially involving the erythroblastic oncogene B2 receptor.

Purpose of the Study:

To review the mechanisms, diagnostic approaches, and therapeutic/preventive strategies for cardiotoxicity associated with anti-human epidermal growth factor receptor 2 therapies.
To provide a comprehensive overview of managing cardiac adverse effects of trastuzumab.

Main Methods:

Review of existing literature on trastuzumab cardiotoxicity.
Discussion of diagnostic tools such as echocardiography, cardiac biomarkers (troponin I, NT-proBNP), and MRI.
Analysis of current and emerging pharmacological interventions.

Main Results:

Cardiotoxicity is a significant concern with trastuzumab therapy.
Early diagnosis is possible through cardiac function assessment and biomarkers.
Established heart failure treatments (e.g., beta-blockers, ACE inhibitors) and newer agents (e.g., ARNIs, SGLT2 inhibitors) show promise.
PCSK9 inhibitors are also being investigated for cardioprotective effects.

Conclusions:

Effective management of trastuzumab cardiotoxicity requires a multi-faceted approach.
Monitoring cardiac function and utilizing appropriate diagnostic tools are essential.
Pharmacological interventions, including established and novel therapies, are key to preventing and treating cardiac adverse events.